



16TH Annual International



VISIT www.chicagolymphoma.com to register today!

The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of

Hodgkin lymphoma and the utility of staging as a guide for treatment.



We are fortunate to have a multitude of the world's experts in lymphoma speaking each year at the conference. The audience comprises regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers. This year's program is the 16th IUCLS.

This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster/abstract presentations, and an opportunity for question-and-answer debates. The IUCLS is a two-day meeting held Friday afternoon and Saturday morning and early afternoon at the InterContinential Chicago Magnificent Mile. Friday afternoon concentrates on the scientific and translational aspects of lymphoma, while Saturday has a clinical focus.

Symposium Co-Chairs

Sonali M. Smith, MD



Elwood V. Jensen Professor of Medicine Section of Hematology/Oncology Director, Lymphoma Program The University of Chicago Chicago, Illinois

Andrew M. Evens, DO, MSc, FACP



Associate Director for Clinical Services Rutgers Cancer Institute Medical Director Oncology Service Line RWJ Barnabas Health Director, Lymphoma Program Division of Blood Disorders Professor of Medicine Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey

Barbara Pro, MD



Professor of Medicine Division of Hematology/Oncology Northwestern University Feinberg School of Medicine Chicago, Illinois







TARGET AUDIENCE

We are fortunate to have a multitude of the world's experts in lymphoma speaking each year at the conference. The audience comprises regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers. This year's program is the 16th IUCLS.

LEARNING OBJECTIVES

After completing this activity, participants should be better able to:

- Distinguish between the different treatment approaches for newly-diagnosed T-cell lymphoma and mantle cell lymphoma
- Discuss the role of allogeneic stem cell transplant in Hodgkin lymphoma treatment
- Identify patient characteristics best suited for CAR T-cell treatment
- Differentiate between the many lymphoma staging and restaging classifications to develop an appropriate patient treatment plan
- Evaluate the different treatment options for follicular lymphoma and the risk of transformation to other cancers
- State key environmental and genetics risks for lymphoma and the roles they play in lymphoid malignancies
- Outline key molecular and cytogenetic information in order to determine best treatment options for chronic lymphocytic leukemia
- Determine short- and long-term toxicities of cardiotoxic agents used in lymphoma treatment
- Describe how epigenetic targets in lymphoid cancers can be used to improve patient outcomes
- List non-chemotherapy options for follicular lymphoma

ACCREDITATION AND CREDIT DESIGNATION

PHYSICIAN CREDIT

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 13.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT

The University of Chicago Medicine is an approved provider of continuing nursing education by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (OBN-001-91) (OH-355, 7/1/2019). This live activity is designated for a maximum of 13.25 continuing nursing education units.

OTHER HEALTHCARE PROFESSIONS CREDIT

Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*TM from organizations accredited by the ACCME, please consult your professional licensing board.

AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

SYMPOSIUM

Advisory Committee

Mehdi Hamadani, MD
Professor of Internal Medicine
Director, BMT & Cellular Therapy
Program
Scientific Director, CIBMTR
Division of Hematology &
Oncology
Medical College of Wisconsin
Milwaukee, WI

Reem Karmali, MD, MS
Assistant Professor, Hematology/
Oncology
Northwestern University
Feinberg School of Medicine
Robert H. Lurie Comprehensive
Cancer Center
Chicago, IL

Justin Kline, MD
Assistant Professor, Department of
Medicine
Section of Hematology/Oncology
The University of Chicago
Medicine
Chicago, IL

David Peace, MD
Professor of Medicine
Division of Hematology/
Medical Oncology
Director, Fellowship Training
Program in Hematology/
Medical Oncology
Chicago, IL

Paul Rubinstein, MD
Attending Physician
Department of Medicine
Section of Hematology/Oncology
Stroger Hospital of Cook County
Assistant Professor of Medicine
Rush University Medical Center
Chicago, IL

Scott Smith, MD, PhD, FACP Professor of Medicine Cardinal Bernardin Cancer Center Loyola University Chicago Medical Center Chicago, IL Girish Venkataraman, MD
Associate Professor and Director,
Immunohistochemistry Lab
Department of Pathology, Section
of Hematopathology
The University of Chicago
Medicine
Chicago, IL

Parameswaran Venugopal, MD Professor of Medicine The Elodia Kehm Chair of Hematology Director, Section of Hematology Rush University Medical Center, Chicago, IL

Jane Winter, MD Professor of Medicine (Hematology and Oncology) Northwestern University Feinberg School of Medicine Chicago, IL

Planning Committee

Sarah Long, MSN, RN Lymphoma Nurse Navigator Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences

Katherine Gacek, BSN, RN, OCN Lymphoma Nurse Navigator Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Trevor Christ, PharmD, BCOP Clinical Pharmacy Specialist in Adult Hematology/Oncology Clinical Coordinator – Inpatient Oncology UChicago Medicine

Jessica Scott
Senior Clinical Research
Coordinator, Lymphoma Program
Department of Medicine, Section
of Hematology/Oncology
The University of Chicago
Medicine & Biological Sciences

Sara Moellering
Assistant Director, Clinical
Research Operations
Department of Medicine, Section
of Hematology/Oncology
The University of Chicago
Biological Sciences

AGENDA AND SPE	AKER SELECTION SUBJECT TO CHANGE.
FRIDAY, APRIL 12, :	2019 -Special Registration Required
TIME	SESSION
7:00 ам — 8:00 ам	Registration and Breakfast
8:00 am - 9:15 am	Welcome & An Overview of the Diagnosis, Prognosis, and Evolving Treatments of Lymphoma
9:15 ам – 9:30 ам	Break
9:30 ам — 11:30 ам	Focus on Survivorship: Short-term and Long-term Toxicity From Pharmacy and Nursing Perspectives
FRIDAY AFTERNOC	N SESSIONS
1:00 рм — 1:10 рм	Introductions
1:10 рм — 1:40 рм	Can We Identify High-risk Follicular Lymphoma Before Starting Treatment? Robert Kridel, MD, MPH, PhD
1:40 рм — 2:10 рм	Liquid Biopsies: Ready for Use in Lymphoma? Mark Roschewski, MD
2:10 рм — 2:40 рм	CAR T-Cell Therapy: Who, How, and Which One Sattva Neelapu, MD
2:40 рм — 3:00 рм	Break
3:00 рм — 3:30 рм	Inherited Cancer Risk in Lymphoid Malignancies: What Do We Tell Our Patients? Jane Churpek, MD
3:30 рм — 4:00 рм	Harnessing Epigenetics in the Treatment of Lymphoma Jennifer Amengual, MD
4:00 рм — 4:30 рм	Targeting Apoptosis in Lymphoid Malignancies: More Than One Tool in the Shed? Alexey Danilov, MD, PhD
4:30 рм — 5:30 рм	Using Molecular and Cytogenetic Information to Sequence Treatments in CLL in 2019 John Seymour, MD, MPH
5:30 рм - 6:30 рм	Wrap-up/Reception & Poster Viewing
SATURDAY, APRIL 1	2, 2019
7:00 ам — 8:00 ам	Registration and Breakfast
8:00 am – 8:10 am	Introductions
8:10 ам — 8:40 ам	CAR T-Cell Therapy: Patient Identification and Integration Into Practice Caron Jacobson, MD
8:40 AM — 9:10 AM	Newly-Diagnosed MCL: Risk Stratification and Optimal Treatment Andre Goy, MD, MS
Q:10 AM = 10:00 AM	State of the Art Treatment Approaches for Newly Diagnosed T Cell Lymphoma

4:00 рм – 4:30 рм	Targeting Apoptosis in Lymphoid Malignancies: More Than One Tool in the Shed? Alexey Danilov, MD, PhD			
4:30 рм — 5:30 рм	Using Molecular and Cytogenetic Information to Sequence Treatments in CLL in 2019 John Seymour, MD, MPH			
5:30 рм - 6:30 рм	Wrap-up/Reception & Poster Viewing			
SATURDAY, APRIL 1	2, 2019			
7:00 ам — 8:00 ам	Registration and Breakfast			
8:00 ам — 8:10 ам	Introductions			
8:10 ам — 8:40 ам	CAR T-Cell Therapy: Patient Identification and Integration Into Practice Caron Jacobson, MD			
8:40 ам — 9:10 ам	Newly-Diagnosed MCL: Risk Stratification and Optimal Treatment Andre Goy, MD, MS			
9:10 ам — 10:00 ам	State of the Art Treatment Approaches for Newly-Diagnosed T-Cell Lymphoma Pier Luigi Zinzani, MD, PhD			
10:00 ам — 10:20 ам	Break			
10:20 ам — 11:00 ам	Debate #1: Allogeneic Stem Cell Transplant Still Has a Role in Hodgkin Lymphoma Miguel Perales, MD-PRO, Craig Moskowitz, MD-CON			
11:00 ам — 11:30 ам	Should AYA Lymphoma Patients Be Treated as Children or Adults? Lisa Roth, MD			
11:30 ам — 12:00 рм	Cardio-Oncology in Lymphoma: How and Why? Jeanne DeCara, MD			
12:00 рм — 12:45 рм	Lunch			
12:45 рм — 1:15 рм	Staging and Restaging in Lymphoma: From Cheson to Lugano to RECIL Mitchell Smith, MD, PhD			
1:15 рм — 1:45 рм	Definition and Optimal Application of "Real World" Data in CLL Anthony Mato, MD, MSCE			
1:45 рм — 2:15 рм	Surrogate End Points in Lymphoma: When do we tell patients, they are "cured"? Matthew Maurer, MD			
2:15 рм — 2:55 рм	Debate #2: Treatment of Follicular Lymphoma Without Chemotherapy Loretta Nastoupil, MD-PRO, Carla Casulo, MD-CON			
2:55 рм — 3:00 рм	Wrap-up			

The conference will be held at the InterContinental Chicago Magnificent Mile located at 505 N. Michigan Avenue. The InterContinental Chicago was built in 1929 and remains a true icon of the great city of Chicago. Situated on the Chicago Magnificent Mile, one block north of the Chicago River, attendees have easy access to restaurants, high-end shopping and all the attractions the city has to offer.

We are pleased to offer a special discounted rate for symposium attendees. Our special rates start at





To reserve a sleeping room attached to the group room block, please call the hotel at 800-628-2112 and identify yourself as part of the Chicago Lymphoma Symposium 2019 or reference booking code F93.

> Should you prefer, you can also book online here: https://www.ihg.com/intercontinental

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine, requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

* All rates are subject to state and city taxes. All reservations must be secured via a valid major credit card. Check-in time is 3 pm and check-out time is 12 pm.

HOW TO REGISTER

ONLINE https://cme.uchicago.edu/iucls2019#group-tabs-node-course-default5

To pay by check, you must mail your registration and payment to:



The University of Chicago Center for Continuing Medical Education c/o Lymphoma IUCLS 2019 5841 S. Maryland Ave., MC1137

Chicago, IL 60637

		MD	Nurse/OHP	Resident/ Fellow	Industry
Symposium AND Friday Morning	Early Bird	\$325	\$150	\$125	\$600
Nursing Session	Regular Registration	\$375	\$175	\$150	\$750
Symposium Only	Early Bird	\$275	\$125	\$100	\$450
Symposium Only	Regular Registration	\$325	\$150	\$125	\$500
Friday Morning	Early Bird	\$100	\$75	\$75	\$150
Nursing Session Only	Regular Registration	\$150	\$100	\$100	\$200

The registration fee for the symposium includes symposium materials, an electronic syllabus, continental breakfast, refreshment breaks, lunch, welcome reception, and poster viewing. You may register online or via U.S. mail. While registration is open until the start of the meeting, we encourage early registration to enable us to provide the best possible service to participants.

PAYMENT

☐ Check enclosed (U.S. funds only), payable to University of Chicago (Tax ID# 36-2177139) ,
Center for Continuing Medical Education, c/o Lymphoma IUCLS 2019, 5841 S. Maryland Ave
MC1137, Chicago, IL 60637

CONTACT	INFORMATIO	N				
Name			Degree			
Email						
	HECK ALL THA					
	heck this box if you c s and exhibitors (if ap	do not want your mailing ac oplicable).	ddress shared v	with conference		
Do you plan to	attend the Friday Po	oster Viewing and Welcome	Reception? [□ YES □ NO		
Please tell us h	ow you found out ab	oout this activity, check all th	nat apply:			
		☐ Brochure	☐ Internet			
i i Ei i i all	i i jouii idi Ad	Previous Attendance				

CANCELLATION POLICY

If you cancel your participation in this conference, your registration fee less a \$100 administrative fee will be refunded when written notification is received by March 12, 2019. No refunds will be made after March 12, 2019.

ACCESSIBILITY

The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at 888-476-9129 or via email at meetings@bioascend.com.

For additional information about this activity, please call the Center for Continuing Medical Education at 773-702-1056.



CHICAGO
MEDICINE &
BIOLOGICAL

SCIENCES

EARLY REGISTRATION
RATES WILL
EXPIRE ON
MARCH 12, 2019

VISIT

ww.chicagolymphoma.com to register today!

Senter for Continuing Medical Education he University of Chicago

5841 S. Maryland Ave., MC1137 Chicago, IL 60637 :/o Lymphoma IUCLS 2019

NON-PROFIT ORG. **PERMIT** #126 **US POSTAGE**



ILTMANN CHICAGO

16TH Annual International

FRIDAY, APRIL 12-

505 N Michigan Ave, Chicago, IL 60611

InterContinental Chicago Magnificent Mile

SATURDAY, APRIL 13, 2019